Macrophage migration inhibitory factor triggers chemotaxis of CD74+CXCR2+NKT cells in chemically induced IFN-γ-Mediated skin inflammation

Journal of Immunology

Volumn 193, Issue 7, 2014, Pages 3693-3703

  Hsieh, Chia Yuan ^a   Chen, Chia Ling ^a,b   Lin, Yee Shin ^a,c   Yeh, Trai Ming ^a,c   Tsai, Tsung Ting ^c   Hong, Ming Yuan ^a   Lin, Chiou Feng ^a,b,c  

^a NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

3 (4 HYDROXYPHENYL) 4,5 DIHYDRO 5 ISOXAZOLE ACETIC ACID METHYL ESTER; CD74 ANTIGEN; CHEMOKINE RECEPTOR CXCR2; CYTOKINE RECEPTOR ANTAGONIST; GAMMA INTERFERON; MACROPHAGE MIGRATION INHIBITION FACTOR; PHORBOL 13 ACETATE 12 MYRISTATE; UNCLASSIFIED DRUG; B LYMPHOCYTE ANTIGEN; CARCINOGEN; HLA ANTIGEN CLASS 2; IFNG PROTEIN, HUMAN; ISOMERASE; MIF PROTEIN, HUMAN; MIF PROTEIN, MOUSE;

ANGIOGENESIS; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; APOPTOSIS; ARTICLE; CELL INFILTRATION; CELL MIGRATION; CELL POPULATION; CELL PROLIFERATION; CELLULAR IMMUNITY; CHEMOTAXIS; CONTROLLED STUDY; CYTOKINE RELEASE; DERMATITIS; HUMAN; HUMAN CELL; IMMUNOSTIMULATION; IN VITRO STUDY; IN VIVO STUDY; INTERFERON PRODUCTION; KERATINOCYTE; MOUSE; NATURAL KILLER CELL MEDIATED CYTOTOXICITY; NATURAL KILLER T CELL; NONHUMAN; PHARMACOLOGICAL BLOCKING; PROTEIN EXPRESSION; PROTEIN TARGETING; T CELL DEPLETION; ACUTE DISEASE; ANIMAL; CELL LINE; CHEMICALLY INDUCED DISORDER; CHRONIC DISEASE; DISEASE MODEL; DRUG ERUPTION; EPIDERMIS; GENETICS; IMMUNOLOGY; INFLAMMATION; INVARIANT CHAIN; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY;

ACUTE DISEASE; ANIMALS; ANTIGENS, DIFFERENTIATION, B-LYMPHOCYTE; CARCINOGENS; CELL LINE; CHRONIC DISEASE; DISEASE MODELS, ANIMAL; DRUG ERUPTIONS; EPIDERMIS; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INFLAMMATION; INTERFERON-GAMMA; INTRAMOLECULAR OXIDOREDUCTASES; KERATINOCYTES; MACROPHAGE MIGRATION-INHIBITORY FACTORS; MICE; NATURAL KILLER T-CELLS; NEOVASCULARIZATION, PATHOLOGIC; RECEPTORS, INTERLEUKIN-8B; TETRADECANOYLPHORBOL ACETATE;

EID: 84907200174     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1400692     Document Type: Article

References (42)

1. De Vry, C. G., M. Valdez, M. Lazarov, E. Muhr, R. Buelow, T. Fong, and S. Iyer. 2005. Topical application of a novel immunomodulatory peptide, RDP58, reduces skin inflammation in the phorbol ester-induced dermatitis model. J. Invest. Derma tol. 125: 473-481.
2. Park, S. Y., D. Gupta, R. Hurwich, C. H. Kim, and R. Dziarski. 2011. Peptidoglycan recognition protein Pglyrp2 protects mice from psoriasis-like skin inflammation by promoting re gulatory T cells and limiting Th17 responses. J. Immunol. 187: 5813-5823.
3. Hsieh, C. Y., C. L. Chen, C. C. Tsai, W. C. Huang, P. C. Tseng, Y. S. Lin, S. H. Chen, T. W. Wong, P. C. Choi, a nd C. F. Lin. 2012. Inhibiting glycogen synthase kinase-3 decreases 12-O-tetradecanoylphorbol-13-acetate-induced interferon-g-mediated skin inflammation. J. Pharmacol. Exp. Ther. 343: 125-133.
4. Schön, M. P., and W. H. Boehncke. 2005. Psoriasis. N. Engl. J. Med. 352: 1899-1912.
5. Nestle, F. O., D. H. Kaplan, and J. Barker. 2009. Psoriasis. N. Engl. J. Med. 361: 496-509.
6. Swamy, M., C. Jamora, W. Havran, and A. Hayday. 2010. Epithelial decision makers: in search of the ?epimmunome.' Nat. Immunol. 11: 656-665.
7. Di Cesare, A., P. Di Meglio, and F. O. Nestle. 2009. The IL-23/Th17 axis in the immunopathogenesis of psoriasis. J. Invest. Dermatol. 129: 1339-1350.
8. Hansel, A., C. Gunther, J. Ingwersen, J. Starke, M. Schmitz, M. Bachmann, M. Meurer, E. P. Rieber, and K. Schakel. 2011. Human slan (6-sulfo LacNAc) dendritic cells are inflammatory dermal dendritic cells in psoriasis and drive strong TH17/TH1 T-cell responses. J. Allergy Clin. Immunol. 127: 787-794.e1-9.
9. Shimizu, T. 2005. Role of macrophage migration inhibitory factor (MIF) in the skin. J. Dermatol. Sci. 37: 65-73.
10. Gilliver, S. C., E. Emmerson, J. Bernhagen, and M. J. Hardman. 2011. MIF: a key player in cutaneous biology and wound healing. Exp. Dermatol. 20: 1-6.
11. Pazyar, N., A. Feily, and R. Yaghoobi. 2013. Macrophage migration inhibitory factor as an incriminating agent in dermatological disorders. Indian J. Dermatol. 58: 157.
12. Liu, A., H. Jin, O. Dirsch, M. Deng, H. Huang, M. Bröcker-Preuss, and U. Dahmen. 2010. Release of danger s ignals during ischemic storage of the liver: a potential marker of organ damagę Mediators Inflamm. 2010: 436145.
13. Bernhagen, J., R. Krohn, H. Lue, J. L. Gregory, A. Zernecke, R. R. Koenen, M. Dewor, I. Georgiev, A. Schober, L. Leng, et al. 2007. MIF is a noncognate ligand of CXC chemokine receptors in inflammatory and atherogenic cell recruitment. Nat. Med. 13: 587-596.
14. Zernec ke, A., J. Bernhagen, and C. Weber. 2008. Macrophage migration inhibitory factor in cardiovascular disease. Circulation 117: 1594-1602.
15. Santos, L. L., A. Dacumos, J. Yamana, L. Sharma, and E. F. Morand. 2008. Reduced arthritis in MIF deficient mice is associated with reduced T cell activation: down-regulation of ERKMAP kinase phosphorylation. Clin. Exp. Immunol. 152: 372-380.
16. Wong, B. L., S. L. Zhu, X. R. Huang, J. Ma, H. H. Xia, R. Bucala, B. C. Wong, and H. Y. Lan. 2009. Essential role for macrophage migration inhibitory factor in gastritis induced by Helicobacter pylori. Am. J. Pathol. 174: 1319-1328.
17. Al-Abed, Y., and S. VanPatten. 2011. MIF as a disease target: ISO-1 as a proofof-concept therapeutic. Future Med. Chem. 3: 45-63.
18. Leng, L., L. Chen, J. Fan, D. Greven, A. Arjona, X. Du, D. Austin, M. Kashgarian, Z. Yin, X. R . Huang, et al. 2011. A small-molecule macrophage migration inhibitory factor antagonist protects against glomerulonephritis in lupus-prone NZB/NZW F1 and MRL/lpr mice. J. Immunol. 186: 527-538.
19. Klein-Szanto, A. J., M. Chiba, S. U. Lee, C. J. Conti, and D. Thetford. 1984. Keratinocyte damage produced by 12-O-tetradecanoylphorbol-13-acetate in rodent epidermis. Carcinogenesis 5: 1459-1465.
20. Pet ernel, S., and M. Kastelan. 2009. Immunopathogenesis of psoriasis: focus on natural killer T cells. J. Eur. Acad. Dermatol. Venereol. 23: 1123-1127.
21. Tobin, A. M., L. Lynch, B. Kirby, and C. O'Farrelly. 2011. Natural killer cells in psoriasis. J. Innate Immun. 3: 403-410.
22. Singh, T. P., C. H. Lee, and J. M. Farber. 2013. Chemokine receptors in psoriasis. Expert Opin. Ther. Targets 17: 1405-1422.
23. Jacobs, R., G. Hintzen, A. Kemper, K. Beul, S. Kempf, G. Behrens, K. W. Sykora, and R. E. Schmidt. 2001. CD56bright cells differ in their KIR repertoire and cytotox ic features from CD56dim NK cells. Eur. J. Immunol. 31: 3121-3127.
24. Cooper, M. A., T. A. Fehniger, and M. A. Caligiuri. 2001. The biology of human natural killer-cell subsets. Trends Immunol. 22: 633-640.
25. Chuang, Y. C., H. Y. Lei, H. S. Liu, Y. S. Lin, T. F. Fu, and T. M. Yeh. 2011. Macrophage migration inhibitory factor induced by dengue virus infection increases vascular permeability. Cytokine 54: 222-231.
26. Gorbachev, A. V., and R. L. Fairchild. 2006. Activated NKT cells increase dendritic cell migration and enhance CD8+ T cell responses in the skin. Eur. J. Immunol. 36: 2494-2503.
27. Steinhoff, M., A. Meinhardt, A. Steinhoff, D. Gemsa, R. Bucala, and M. Bacher. 1999. Evidence for a role of macrophage migration inhibitory factor in psoriatic skin disease. Br. J. Dermatol. 141: 1061-1066.
28. Shimizu, T., J. Nishihira, Y. Mizue, H. Nakamura, R. Abe, H. Watanabe, A. Ohkawara, and H. Shimizu. 2001. High macrophage migration inhibitory factor (MIF) serum levels associated with extended psoriasis. J. Invest. Dermatol. 116: 989-990.
29. Schö n, M. P. 2008. Animal models of psoriasis: a critical appraisal. Exp. Dermatol. 17: 703-712.
30. Donn, R. P., D. Plant, F. Jury, H. L. Richards, J. Worthington, D. W. Ray, and C. E. Griffiths. 2004. Macrophage migration inhibitory factor gene polymorphism is associated with psoriasis. J. Invest. Dermatol. 123: 484-487.
31. Wu, J., F. Chen, X. Zhang, Y. Li, H. Ma, Y. Zhou, Y. Jin, H. Wang, J. Bai, G. Zhang, and S. Fu. 2009. Association of MIF promoter polymorphisms with psoriasis in a Ha n population in northeastern China. J. Dermatol. Sci. 53: 212-215.
32. Gesser, B., M. K. Rasmussen, L. Raaby, C. Rosada, C. Johansen, R. B. Kjellerup, K. Kragballe, and L. Iversen. 2011. D imethylfumarate inhibits MIF-induced proliferation of keratinocytes by inhibiting MSK1 and RSK1 activation and by inducing nuclear p-c-Jun (S63) and p-p53 (S15) expression. Inflamm. Res. 60: 643-653.
33. Szegedi, A., M. Aleksza, A. Gonda, B. Irinyi, S. Sipka, J. Hunyadi, and P. Antal-Szalmá s. 2003. Elevated rate of Thelper1 (T(H)1) lymphocytes and serum IFNgamma levels in psoriatic patients. Immunol. Lett. 86: 277-280.
34. Yao, Y., L. Richman, C. Morehouse, M. de los Reyes, B. W. Higgs, A. Boutrin, B. White, A. Coyle, J. Krueger, P. A. Kiener, and B. Jallal. 2008. Type I interferon: potential therapeutic target for psoriasis? PLo S ONE 3: e2737.
35. Hald, A., R. M. André s, M. L. Salskov-Iversen, R. B. Kjellerup, L. Iversen, and C. Johansen. 2013. STAT1 expression and activation is increased in lesional psoriatic skin. Br. J. Dermatol. 168: 302-310.
36. Nomura, I., E. Goleva, M. D. Howell, Q. A. Hamid, P. Y. Ong, C. F. Hall, M. A. Darst, B. Gao, M. Boguniewicz, J. B. Travers, and D. Y. Leung. 2003. Cytokine milieu of atopic dermatitis, as compared to psoriasis, skin prevents induction of innate immune response genes. J. Immunol. 171: 3262-3269.
37. Balato, A., D. Unutmaz, and A. A. Gaspari. 2009. Natural killer T cells: an unconventional T-cell subset with diverse effector and regulatory functions. J. Invest. Dermatol. 129: 1628-1642.
38. Bonish, B., D. Jullien, Y. Dutronc, B. B. Huang, R. Modlin, F. M. Spada, S. A. Porcelli, and B. J. Nickoloff. 2000. Overexpression of CD1d by keratinocytes in psoriasis and CD1d-dependent IFN-gamma production by NK-T cells. J. Immunol. 165: 4076-4085.
39. Cameron, A. L., B. Kirby, W. Fei, and C. E. Griffiths. 2002. Natural killer and natural killer-T cells in psoriasis. Arch. Dermatol. Res. 294: 363-369.
40. Johnston, B., C. H. Kim, D. Soler, M. Emoto, and E. C. Butcher. 2003. Differential chemokine responses and homing patterns of murine TCR alpha beta NKT cell subsets. J. Immunol. 171: 2960-2969.
41. Apte, R. S., D. Sinha, E. Mayhew, G. J. Wistow, and J. Y. Niederkorn. 1998. Cutting edge: role of macrophage migration inhibitory factor in inhibiting NK cell activity and preserving immune privilege. J. Immun ol. 160: 5693-5696.
42. Takagi D.,K. Iwabuchi,M. Maeda,Y. Nakamaru,Y. Furuta,S. Fukuda,L. Van Kaer,J. Nishihira,K. Onoé, 2006, Natural killer T cells ameliorate antib odyinduced arthritis in macrophage migration inhibitory factor transgenic mice,Int. J. Mol. Med., 18 , 829-836.